ClinicalTrials.gg
Active, not recruitingNCT03317392Updated Nov 13, 2026Results posted

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

A Phase 1/2 interventional study of Biopsy Procedure and Biospecimen Collection in Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma and Stage IVB Prostate Cancer AJCC v8, sponsored by National Cancer Institute (NCI). Active, not recruiting at 22 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by National Cancer Institute (NCI) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing olaparib in Prostatic Neoplasms — 2 open to participants now, 11 under way, 2 of them phase 3. olaparib · Prostatic Neoplasms.

Enrollment
6th of 25
132 · median 43
Started
2019
with 4 others
Phase 1/2
2 of 25
none open now
Primary completion
2025-03
later than 4 of 10 live
Registered
8th of 25
by date
Lead sponsor
1 of 25
National Cancer Institute (NCI)

Among the 25 studies testing olaparib in Prostatic Neoplasms, this one is the 6th largest by enrollment, is one of 5 that started in 2019, is one of 2 in phase 1/2, reaches primary completion later than 4 of the 10 other live ones, and was the 8th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

2 of the 25 studies testing olaparib in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing olaparib in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This phase I/II trial studies the best dose and side effects of olaparib and how well it works with radium Ra 223 dichloride in treating patients with castration-resistant prostate cancer that has spread to the bone and other places in the body (metastatic). PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Radioactive drugs, such as radium Ra 223 dichloride, may carry radiation directly to tumor cells and not harm normal cells. Giving olaparib and radium Ra 223 dichloride may help treat patients with castration-resistant prostate cancer.

Read the detailed description

PRIMARY OBJECTIVES:

I. Determine the maximum tolerated dose (MTD) of olaparib in combination with radium Ra 223 dichloride (radium-223). (Phase I) II. Evaluate the radiographic progression-free survival (rPFS). (Phase II)

SECONDARY OBJECTIVES:

I. Evaluate safety and tolerability as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

II. To evaluate rPFS as stratified by disease extent (=\< 20 or > 20 bone lesions) and prior docetaxel use (yes or no).

III. Evaluate rPFS in patients harboring or lacking evidence of homologous recombination deficiency (HRD).

IV. Evaluate rPFS in patients based on prior abiraterone and/or next generation androgen receptor (AR) antagonist (enzalutamide, apalutamide, darolutamide or other agent) use (yes versus no) for either hormone sensitive or castration resistant prostate cancer (CRPC).

V. Evaluate prostate specific antigen (PSA) response rate as defined by >= 50% decline in PSA from baseline.

VI. Evaluate total alkaline phosphatase response defined as a reduction of >= 30% from the baseline value, confirmed >= 4 weeks later.

VII. Evaluate time to PSA progression as defined by Prostate Cancer Clinical Trials Working Group (PCTWG) 3 criteria.

VIII. Evaluate radiographic objective response rate as defined by Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1.

IX. Evaluate time to increase in the total alkaline phosphatase (ALP) level defined as an increase of >= 25% from baseline at >= 12 weeks, in patients with no decrease from baseline, or as an increase of >= 25% above the nadir, confirmed >= 3 weeks later, in patients with an initial decrease from baseline.

X. Evaluate time to first subsequent anti-cancer therapy (including AR signaling agents, cytotoxic chemotherapy, immunotherapy, or investigational agents) or death.

XI. Evaluate time to first symptomatic skeletal event (SSE). XII. Evaluate overall survival (OS).

EXPLORATORY OBJECTIVES:

I. Evaluate impact on quality of life (QOL) as determined by Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire and Brief Pain Inventory (BPI).

II. Estimate the frequency of mutations in the deoxyribonucleic acid (DNA) repair pathway in patients with metastatic castration-resistant prostate cancer (CRPC) as determine by Oncopanel testing and by whole exome sequencing (WES).

III. Characterize changes in ribonucleic acid (RNA) expression of DNA repair genes and immune markers by whole transcriptome sequencing (WTS) in each arm.

IV. Characterize changes in immune cell, T-cell receptor (TCR), and B-cell (BCR) receptor repertoire at baseline, during treatment, and at progression in each arm.

V. Evaluate changes in lactate dehydrogenase (LDH) in patients each treatment arm.

VI. Assess the prevalence of germline mutations in homologous recombination genes in all enrolled patients.

VII. Correlate homologous recombination gene germline mutation status with PSA response by treatment arm.

VIII. Evaluate family history of cancers in the study population and correlate family cancer history with germline mutation status.

IX. Correlate presence or absence of RAD51 with somatic and germline homologous recombination gene mutation status, PSA response, and PFS between treatment arms.

X. Evaluate the changes in whole genome sequencing (WGS) of plasma cell-free circulating DNA (cfDNA) based patient-tumor specific signature at baseline, on treatment, and at progression.

XI. Evaluate tumor mutation burden (TMB) and tumor mutational signature in plasma cfDNA at baseline and correlate to tumor tissue TMB and mutational signature.

OUTLINE: This is a phase I, dose-escalation study of olaparib followed by a phase II study.

PHASE I: Patients receive radium Ra 223 dichloride intravenously (IV) over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive olaparib orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) or magnetic resonance imaging (MRI) as well as blood sample collection and a tissue biopsy during screening and on study.

PHASE II: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive radium Ra 223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI as well as blood sample collection and a tissue biopsy during screening and on study.

ARM II: Patients receive radium Ra 223 dichloride as in Arm I. Patients with radiographic progression may crossover to Arm I. If patients have already completed all 6 infusions of radium, they will receive monotherapy with olaparib. If they have not yet completed all 6 radium-223 infusion, they will continue radium-223 infusion until completion and receive concurrent treatment with olaparib. Patients also undergo CT or MRI as well as blood sample collection and a tissue biopsy during screening and on study.

After completion of study treatment, patients are followed up every 6 months for 2 years.

03

Conditions studied

  • Castration-Resistant Prostate Carcinoma
  • Metastatic Prostate Adenocarcinoma
  • Stage IVB Prostate Cancer AJCC v8

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be male aged >= 18 years of age
  • Participants must have or cytologically confirmed adenocarcinoma of the prostate
  • Participants must have castrate levels of serum testosterone \< 50 ng/dL
  • Participants without orchiectomy must be maintained on luteinizing hormone releasing hormone (LHRH) agonist/antagonist; participants receiving prior docetaxel abiraterone, or next generation AR antagonist (enzalutamide, apalutamide, or darolutamide) for hormone sensitive disease are permitted
  • Participants must have progressive disease as defined by any of the following:

    • Castrate resistant disease as defined by PCWG-3 criteria; participants must have a rise in PSA on two successive determination at least one week apart and PSA levels >= 2 ng/mL (only the screening PS needs to be >= 2 ng/mL) and serum testosterone \< 50 ng/dL
    • Soft tissue progression as defined by version 1.1
    • Bone disease progression as defined by PCWG-3 criteria including the development of two or more new lesions on bone scan
  • Participants must have >= 2 bone by radiographic imaging and at least 1 lesion which has not been treated with prior radiation therapy
  • Participants must have tumor accessible for and be agreeable to baseline tumor biopsy; a metastatic focus is preferred but if not available and prostate is still intact prostate biopsy can be performed
  • Availability at the study site of formalin-fixed, paraffin-embedded (FFPE) archival tumor specimens, when available
  • (ECOG) performance status =\< 1 ( >= 80%)
  • White blood cell count (WBC) >= 3,000/mcL (within 28 days prior to administration of study treatment)
  • (ANC) >= 1,500/mcL (within 28 days prior to administration of study treatment)
  • >= 100,000/mcL (within 28 days prior to administration of study treatment)
  • >= 10 g/dL (transfusions permitted) (within 28 days prior to administration of study treatment)
  • Total =\< 1.5 x the institutional (ULN) (within 28 days prior to administration of study treatment); for subjects with Gilbert's disease =\< 3.0 mg/dL
  • (AST)/alanine aminotransferase (ALT) =\< 3 x institutional ULN (within 28 days prior to administration of study treatment)
  • >= 51 ml/min as defined by Cockcroft-Gault equation (within 28 days prior to administration of study treatment)
  • Participants should be receiving an osteoclast targeting agent including either bisphosphonates or denosumab except in patients with as determined by the treating investigator including:

    • Hypocalcemia
    • Hypophosphatemia
    • Renal impairment including those with a \< 35 mL/min using the Cockcroft-Gault equation
    • to drug formulation
    • Dental condition or need for dental intervention that per the investigator would increase the risk of osteonecrosis of the jaw
  • The effects of olaparib and radium-223 on the developing human fetus are unknown; for this reason, men treated or enrolled on this protocol must agree to use adequate and avoid sperm donation prior to the study, for the duration of study participation, and three months after discontinuation of olaparib and radium-223 administration
  • (HIV)-positive with negative viral loads on stable antiretroviral regimen and > 250 are eligible
  • Ability to understand and the willingness to sign a written document; patients with impaired decision-making who have a legal guardian (e.g., spouse) able to make informed decisions on behalf of the patient are eligible
  • Patients must be able to tolerate oral medications by mouth and not have a gastrointestinal illness that would preclude absorption of olaparib

Exclusion criteria

Exclusion Criteria:

  • Pathology consistent with small cell carcinoma of the prostate
  • Presence of visceral (liver, lung, brain, etc.) or malignant lymphadenopathy exceeding 4 centimeters (cm) in short diameter
  • Prior treatment with radium-223
  • Prior treatment with olaparib or other PARPi
  • Treatment with abiraterone, apalutamide, or darolutamide within 2 weeks of treatment initiation; treatment with cytotoxic chemotherapy within 3 weeks of treatment initiation; treatment with prostate cancer directed therapy within 4 weeks of treatment initiation; treatment with enzalutamide within 4 weeks of treatment initiation
  • Prior hemibody external radiotherapy
  • Palliative radiation therapy to the bone or other sites within 2 weeks of treatment initiation
  • Participants who are receiving any other investigational agents
  • Imminent or established spinal cord compression based on clinical and/or imaging findings
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring need for intravenous anti-microbials, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • medical condition defined as:

    • Cerebral infarction within 6 months of study treatment
    • within 3 months of study treatment
    • Myocardial infarction within 6 months of study treatment
    • Uncontrolled angina within 3 months of study treatment
    • Congestive heart failure (NYHA) class 3 or 4, or subjects with history of congestive heart failure NYHA class 3 or 4 in the past, or history of anthracycline or anthracenedione (mitoxantrone) treatment, unless a screening echocardiogram or multi-gated acquisition scan performed within 3 months of the screening visit results in a that is >= 45%
    • History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsade de pointes)
    • Prolonged interval by the Fridericia correction formula on the screening (ECG) > 470 msec (as determined on 2 or more time points within a 24 hour period if the first ECG demonstrates a prolonged corrected QT interval) or family history of long QT syndrome
    • History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place
    • Uncontrolled hypertension as indicated by a resting systolic blood pressure > 170 mmHg or diastolic blood pressure > 105 mmHg at the screening visit
    • History of hypertensive emergency or encephalopathy within 6 months of study treatment
    • Deep venous thrombosis or pulmonary embolism within 3 months of study treatment
  • Major surgery within 4 weeks of study treatment; subjects with clinically relevant ongoing complications from prior surgery are not eligible
  • History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug
  • Patient unable to swallow orally administered medication
  • History of bowel obstruction within 1 month of study treatment
  • History of abdominal fistula, intra-abdominal abscess, or gastrointestinal perforation within the 3 months of study treatment
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib or radium-223
  • Participants receiving strong /5 inducers or inhibitors are ineligible; dihydropyridine calcium-channel blockers are permitted for management of hypertension; the required prior to starting olaparib is 2 weeks for CYP3A inhibitors; the required washout period prior to starting olaparib is 4 weeks for enzalutamide or phenobarbital and 3 weeks for other CYP3A inducers
  • Patients with known active hepatitis (i.e. or C) infection
  • Patients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML
  • Patient having received prior allogenic bone marrow transplant or double umbilical cord blood transplantation
  • Individuals with a history of a different are ineligible except for the following circumstances:

    • Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy, or
    • Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: superficial bladder cancer, basal cell or squamous cell carcinoma of the skin
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    Phase I (radium Ra 223 dichloride, olaparib)

    Patients in Phase I receive radium Ra 223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI as well as blood sample collection and a tissue biopsy during screening and on study.

    Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Other: Laboratory Biomarker Analysis · Procedure: Magnetic Resonance Imaging · Drug: Olaparib · Other: Quality-of-Life Assessment · Radiation: Radium Ra 223 Dichloride

  • Experimental
    Phase II Arm I (radium Ra 223 dichloride, olaparib)

    Patients in Phase II Arm I receive radium Ra 223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI as well as blood sample collection and a tissue biopsy during screening and on study.

    Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Other: Laboratory Biomarker Analysis · Procedure: Magnetic Resonance Imaging · Drug: Olaparib · Other: Quality-of-Life Assessment · Radiation: Radium Ra 223 Dichloride

  • Experimental
    Phase II Arm II (radium Ra 223 dichloride)

    Patients in Phase 2 Arm II receive radium Ra 223 dichloride as in Arm I. Patients with radiographic progression may crossover to Arm I. If patients have already completed all 6 infusions of radium, they will receive monotherapy with olaparib. If they have not yet completed all 6 radium-223 infusion, they will continue radium-223 infusion until completion and receive concurrent treatment with olaparib. Patients also undergo CT or MRI as well as blood sample collection and a tissue biopsy during screening and on study.

    Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Other: Laboratory Biomarker Analysis · Procedure: Magnetic Resonance Imaging · Other: Quality-of-Life Assessment · Radiation: Radium Ra 223 Dichloride

Interventions

  • ProcedureBiopsy Procedure

    Undergo tissue biopsy

    Also known as: Biopsy, BIOPSY_TYPE, Bx

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureComputed Tomography

    Undergo CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • Given PO

    Also known as: AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

  • RadiationRadium Ra 223 Dichloride

    Given IV

    Also known as: Alpharadin, BAY 88-8223, BAY88-8223, Radium 223 Dichloride, RADIUM RA-223 DICHLORIDE, Radium-223 Chloride, Radium-223 Dichloride, Xofigo

06

What researchers measure

Primary outcomes

  1. Phase I: Maximum Tolerated Dose

    Determine the maximum tolerated dose (MTD) of olaparib in combination with radium Ra 223 dichloride (radium-223). (Phase I)

    Time frame: 56 days

  2. Phase II: Radiographic Progression-free Survival (rPFS)

    Radiographic progression is defined by Prostate Cancer Working Group 3 criteria for bone metastases and RECIST version 1.1 for non-bone metastases. Median rPFS will be estimated using the Kaplan-Meier method by treatment arm. A stratified Cox proportional hazards regression model will estimate the rPFS treatment hazard ratio with 80% 2-sided confidence intervals (CIs). Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions",

    Time frame: From randomization to date of radiographic progression or death due to any cause, whichever occurs first, or censored at the date of last disease assessment. Up to approximately 2 years

Secondary outcomes

  1. Phase II: rPFS in Patients Without Prior Docetaxel

    Median rPFS will be estimated using the Kaplan-Meier method by treatment arm.

    Time frame: Up to approximately 2 years after randomization

  2. Phase II: rPFS in Patients With Prior Docetaxel

    Median rPFS will be estimated using the Kaplan-Meier method by treatment arm.

    Time frame: Up to approximately 2 years after randomization

  3. Phase II: rPFS in Patients With ≤ 20 Bone Lesions

    Median rPFS will be estimated using the Kaplan-Meier method by treatment arm.

    Time frame: Up to approximately 2 years after randomization

  4. Phase II: rPFS in Patients With > 20 Bone Lesions

    Median rPFS will be estimated using the Kaplan-Meier method by treatment arm.

    Time frame: Up to approximately 2 years after randomization

  5. Phase II: Overall Survival (OS)

    Phase II: Median OS will be estimated using the method of Kaplan-Meier.

    Time frame: From randomization to the date of death due to any cause, or censored at the date of last follow-up, assessed up to 3.5 years

Other outcomes

  1. Phase II: rPFS in Patients Without Homologous Recombination Deficiency

    rPFS in patients without homologous recombination deficiency

    Time frame: Up to approximately 2 years after randomization

  2. Phase II: rPFS in Patients With Homologous Recombination Deficiency

    rPFS in patients with homologous recombination deficiency

    Time frame: Up to approximately 2 years after randomization

  3. Phase II: Prostate Specific Antigen (PSA) Response

    Number of participants with prostate specific antigen (PSA) response defined as PSA ≥50% decrease from baseline

    Time frame: Up to approximately 2 years after randomization

  4. Phase II: Alkaline Phosphatase (ALP) Response

    Alkaline phosphatase (ALP) response defined as ≥30% decrease from baseline.

    Time frame: Up to approximately 2 years after randomization

  5. Phase II: Symptomatic Skeletal Event (SSE)

    Symptomatic skeletal event (SSE) defined as pathologic bone fracture, spinal cord compression, or radiation therapy to bone.

    Time frame: Up to approximately 2 years after randomization

  6. Phase II: Incidence of Grade 3 or Higher Treatment Related Adverse Events (TrAE)

    Incidence of grade 3 or higher treatment related adverse events (TrAE)

    Time frame: Up to approximately 2 years after randomization

07

Results

Posted May 5, 2026

Participant flow

Participant flow — Overall Study
MilestonePhase I Radium223+Olaparib Dose Level 1Phase I Radium223+Olaparib Dose Level 2Phase II Arm I (Radium Ra 223 Dichloride, Olaparib)Phase II Arm II (Radium Ra 223 Dichloride)
Started666159
Completed665955
Not completed0024
Withdrew: Did not receive study therapy0024

Outcome measures

PrimaryPhase I: Maximum Tolerated Dose

Determine the maximum tolerated dose (MTD) of olaparib in combination with radium Ra 223 dichloride (radium-223). (Phase I)

Time frame:
56 days
Reported as:
Number · mg
Phase I: Maximum Tolerated Dose
mgPhase I Radium223+Olaparib Dose Level 1Phase I Radium223+Olaparib Dose Level 2
Phase I: Maximum Tolerated Dose200200
PrimaryPhase II: Radiographic Progression-free Survival (rPFS)

Radiographic progression is defined by Prostate Cancer Working Group 3 criteria for bone metastases and RECIST version 1.1 for non-bone metastases. Median rPFS will be estimated using the Kaplan-Meier method by treatment arm. A stratified Cox proportional hazards regression model will estimate the rPFS treatment hazard ratio with 80% 2-sided confidence intervals (CIs). Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions",

Time frame:
From randomization to date of radiographic progression or death due to any cause, whichever occurs first, or censored at the date of last disease assessment. Up to approximately 2 years
Reported as:
Median · months
Phase II: Radiographic Progression-free Survival (rPFS)
monthsPhase II Arm I (Radium Ra 223 Dichloride, Olaparib)Phase II Arm II (Radium Ra 223 Dichloride)
Phase II: Radiographic Progression-free Survival (rPFS)8.9 (5.4 to 13.7)4.7 (3.2 to 6.0)
SecondaryPhase II: rPFS in Patients Without Prior Docetaxel

Median rPFS will be estimated using the Kaplan-Meier method by treatment arm.

Time frame:
Up to approximately 2 years after randomization
Reported as:
Median · months
Phase II: rPFS in Patients Without Prior Docetaxel
monthsPhase II Arm I (Radium Ra 223 Dichloride, Olaparib)Phase II Arm II (Radium Ra 223 Dichloride)
Phase II: rPFS in Patients Without Prior Docetaxel13.7 (11.3 to 17.2)5.7 (3.3 to 8.3)
SecondaryPhase II: rPFS in Patients With Prior Docetaxel

Median rPFS will be estimated using the Kaplan-Meier method by treatment arm.

Time frame:
Up to approximately 2 years after randomization
Reported as:
Median · months
Phase II: rPFS in Patients With Prior Docetaxel
monthsPhase II Arm I (Radium Ra 223 Dichloride, Olaparib)Phase II Arm II (Radium Ra 223 Dichloride)
Phase II: rPFS in Patients With Prior Docetaxel6.6 (3.3 to 8.9)3.3 (2.9 to 5.6)
SecondaryPhase II: rPFS in Patients With ≤ 20 Bone Lesions

Median rPFS will be estimated using the Kaplan-Meier method by treatment arm.

Time frame:
Up to approximately 2 years after randomization
Reported as:
Median · months
Phase II: rPFS in Patients With ≤ 20 Bone Lesions
monthsPhase II Arm I (Radium Ra 223 Dichloride, Olaparib)Phase II Arm II (Radium Ra 223 Dichloride)
Phase II: rPFS in Patients With ≤ 20 Bone Lesions13.4 (11.3 to 17.0)4.1 (2.9 to 5.7)
SecondaryPhase II: rPFS in Patients With > 20 Bone Lesions

Median rPFS will be estimated using the Kaplan-Meier method by treatment arm.

Time frame:
Up to approximately 2 years after randomization
Reported as:
Median · months
Phase II: rPFS in Patients With > 20 Bone Lesions
monthsPhase II Arm I (Radium Ra 223 Dichloride, Olaparib)Phase II Arm II (Radium Ra 223 Dichloride)
Phase II: rPFS in Patients With > 20 Bone Lesions4.7 (3.1 to 8.8)4.8 (3.1 to 11.0)
SecondaryPhase II: Overall Survival (OS)

Phase II: Median OS will be estimated using the method of Kaplan-Meier.

Time frame:
From randomization to the date of death due to any cause, or censored at the date of last follow-up, assessed up to 3.5 years
Reported as:
Median · months
Phase II: Overall Survival (OS)
monthsPhase II Arm I (Radium Ra 223 Dichloride, Olaparib)Phase II Arm II (Radium Ra 223 Dichloride)
Phase II: Overall Survival (OS)20.2 (13.8 to 25.7)21.1 (14.4 to 23.7)
Other pre-specifiedPhase II: rPFS in Patients Without Homologous Recombination Deficiency

rPFS in patients without homologous recombination deficiency

Time frame:
Up to approximately 2 years after randomization
Reported as:
Median · months
Phase II: rPFS in Patients Without Homologous Recombination Deficiency
monthsPhase II Arm I (Radium Ra 223 Dichloride, Olaparib)Phase II Arm II (Radium Ra 223 Dichloride)
Phase II: rPFS in Patients Without Homologous Recombination Deficiency5.7 (3.1 to 15.8)5.6 (3.3 to 11.0)
Other pre-specifiedPhase II: rPFS in Patients With Homologous Recombination Deficiency

rPFS in patients with homologous recombination deficiency

Time frame:
Up to approximately 2 years after randomization
Reported as:
Median · months
Phase II: rPFS in Patients With Homologous Recombination Deficiency
monthsPhase II Arm I (Radium Ra 223 Dichloride, Olaparib)Phase II Arm II (Radium Ra 223 Dichloride)
Phase II: rPFS in Patients With Homologous Recombination Deficiency13.9 (4.7 to 99)3.0 (2.9 to 10.0)
Other pre-specifiedPhase II: Prostate Specific Antigen (PSA) Response

Number of participants with prostate specific antigen (PSA) response defined as PSA ≥50% decrease from baseline

Time frame:
Up to approximately 2 years after randomization
Reported as:
Count of participants · Participants
Phase II: Prostate Specific Antigen (PSA) Response
ParticipantsPhase II Arm I (Radium Ra 223 Dichloride, Olaparib)Phase II Arm II (Radium Ra 223 Dichloride)
Phase II: Prostate Specific Antigen (PSA) Response99
Other pre-specifiedPhase II: Alkaline Phosphatase (ALP) Response

Alkaline phosphatase (ALP) response defined as ≥30% decrease from baseline.

Time frame:
Up to approximately 2 years after randomization
Reported as:
Count of participants · Participants
Phase II: Alkaline Phosphatase (ALP) Response
ParticipantsPhase II Arm I (Radium Ra 223 Dichloride, Olaparib)Phase II Arm II (Radium Ra 223 Dichloride)
Phase II: Alkaline Phosphatase (ALP) Response3030
Other pre-specifiedPhase II: Symptomatic Skeletal Event (SSE)

Symptomatic skeletal event (SSE) defined as pathologic bone fracture, spinal cord compression, or radiation therapy to bone.

Time frame:
Up to approximately 2 years after randomization
Reported as:
Number · Percent of participants
Phase II: Symptomatic Skeletal Event (SSE)
Percent of participantsPhase II Arm I (Radium Ra 223 Dichloride, Olaparib)Phase II Arm II (Radium Ra 223 Dichloride)
Phase II: Symptomatic Skeletal Event (SSE)12.7 (4.9 to 24.2)22.9 (9.5 to 39.7)
Other pre-specifiedPhase II: Incidence of Grade 3 or Higher Treatment Related Adverse Events (TrAE)

Incidence of grade 3 or higher treatment related adverse events (TrAE)

Time frame:
Up to approximately 2 years after randomization
Reported as:
Number · events
Phase II: Incidence of Grade 3 or Higher Treatment Related Adverse Events (TrAE)
eventsPhase II Arm I (Radium Ra 223 Dichloride, Olaparib)Phase II Arm II (Radium Ra 223 Dichloride)
Phase II: Incidence of Grade 3 or Higher Treatment Related Adverse Events (TrAE)4423

Adverse events

Collected over Adverse events (AE) are assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5 by treatment arm, from enrollment until end of study visit, up to approximately 2.5 years after randomization. All-Cause Mortality monitored/assessed up to 3.5 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase I Radium223+Olaparib Dose Level 16/6 (100%)4/6 (66.7%)6/6 (100%)
Phase I Radium223+Olaparib Dose Level 23/6 (50%)2/6 (33.3%)6/6 (100%)
Phase II Arm I (Radium Ra 223 Dichloride, Olaparib)38/61 (62.3%)39/59 (66.1%)59/59 (100%)
Phase II Arm II (Radium Ra 223 Dichloride)18/59 (30.5%)29/55 (52.7%)55/55 (100%)
Phase II Arm I After Cross-over From Arm II (Radium Ra 223 Dichloride, Olaparib)16/23 (69.6%)11/23 (47.8%)23/23 (100%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventPhase I Radium223+Olaparib Dose Level 1Phase I Radium223+Olaparib Dose Level 2Phase II Arm I (Radium Ra 223 Dichloride, Olaparib)Phase II Arm II (Radium Ra 223 Dichloride)Phase II Arm I After Cross-over From Arm II (Radium Ra 223 Dichloride, Olaparib)
Lymphocyte count decreasedInvestigations0/62/618/598/556/23
AnemiaBlood and lymphatic system disorders2/61/613/5910/552/23
Platelet count decreasedInvestigations1/60/65/593/550/23
DyspneaRespiratory, thoracic and mediastinal disorders1/60/61/593/552/23
HematuriaRenal and urinary disorders1/60/61/591/550/23
Lung infectionInfections and infestations1/60/61/590/550/23
Aspartate aminotransferase increasedInvestigations1/60/60/590/550/23
HypertensionVascular disorders0/60/64/593/550/23
White blood cell decreasedInvestigations0/60/64/591/551/23
Neutrophil count decreasedInvestigations0/60/63/593/551/23
Most frequent other events
Showing 10 of 98
Most frequent other events
EventPhase I Radium223+Olaparib Dose Level 1Phase I Radium223+Olaparib Dose Level 2Phase II Arm I (Radium Ra 223 Dichloride, Olaparib)Phase II Arm II (Radium Ra 223 Dichloride)Phase II Arm I After Cross-over From Arm II (Radium Ra 223 Dichloride, Olaparib)
FatigueGeneral disorders6/65/640/5928/556/23
AnemiaBlood and lymphatic system disorders3/64/644/5932/5514/23
Lymphocyte count decreasedInvestigations0/64/633/5927/5513/23
White blood cell decreasedInvestigations0/64/631/5927/5510/23
NauseaGastrointestinal disorders3/63/630/5921/558/23
DiarrheaGastrointestinal disorders3/62/628/5922/556/23
PainGeneral disorders3/61/614/5910/557/23
AnorexiaMetabolism and nutrition disorders2/62/619/5921/559/23
HyperglycemiaMetabolism and nutrition disorders0/61/612/5915/559/23
Blood lactate dehydrogenase increasedInvestigations1/61/613/598/559/23

Baseline characteristics

Age, Continuous
Age, Continuous(years)Phase I Radium223+Olaparib Dose Level 1Phase I Radium223+Olaparib Dose Level 2Phase II Arm I (Radium Ra 223 Dichloride, Olaparib)Phase II Arm II (Radium Ra 223 Dichloride)Total
Median67 (64 to 73)68 (66 to 69)69 (63 to 77)71 (66 to 76)70 (65 to 76)
Sex: Female, Male
Sex: Female, Male(Participants)Phase I Radium223+Olaparib Dose Level 1Phase I Radium223+Olaparib Dose Level 2Phase II Arm I (Radium Ra 223 Dichloride, Olaparib)Phase II Arm II (Radium Ra 223 Dichloride)Total
Female00000
Male666159132
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase I Radium223+Olaparib Dose Level 1Phase I Radium223+Olaparib Dose Level 2Phase II Arm I (Radium Ra 223 Dichloride, Olaparib)Phase II Arm II (Radium Ra 223 Dichloride)Total
American Indian or Alaska Native00000
Asian00202
Native Hawaiian or Other Pacific Islander00000
Black or African American00369
White655350114
More than one race00000
Unknown or Not Reported01337
Region of Enrollment
Region of Enrollment(participants)Phase I Radium223+Olaparib Dose Level 1Phase I Radium223+Olaparib Dose Level 2Phase II Arm I (Radium Ra 223 Dichloride, Olaparib)Phase II Arm II (Radium Ra 223 Dichloride)Total
United States666159132
Previous use of androgen receptor pathway inhibitors
Previous use of androgen receptor pathway inhibitors(Participants)Phase I Radium223+Olaparib Dose Level 1Phase I Radium223+Olaparib Dose Level 2Phase II Arm I (Radium Ra 223 Dichloride, Olaparib)Phase II Arm II (Radium Ra 223 Dichloride)Total
Count of participants665956127
Previous use of any chemotherapy
Previous use of any chemotherapy(Participants)Phase I Radium223+Olaparib Dose Level 1Phase I Radium223+Olaparib Dose Level 2Phase II Arm I (Radium Ra 223 Dichloride, Olaparib)Phase II Arm II (Radium Ra 223 Dichloride)Total
Count of participants21343067
Previous use of docetaxel
Previous use of docetaxel(Participants)Phase I Radium223+Olaparib Dose Level 1Phase I Radium223+Olaparib Dose Level 2Phase II Arm I (Radium Ra 223 Dichloride, Olaparib)Phase II Arm II (Radium Ra 223 Dichloride)Total
Count of participants21323065
08

Study locations

22 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Mar 2025, 73 months.

Results were first posted in May 2026, 1 year 1 month after primary completion.

Of 114 non-industry phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 85. This study's 73 months is above that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2017
First posted
Oct 23, 2017
StartActual
Feb 4, 2019
Primary completionActual
Mar 31, 2025
CompletionEst.
Feb 16, 2027
Results first posted
May 5, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03317392
Responsible party
Sponsor
First posted
Oct 23, 2017
Start date
Feb 4, 2019
Primary completion
Mar 31, 2025
Completion
Feb 16, 2027 (estimated)
Results posted
May 5, 2026
Last update
Nov 13, 2026

Study contacts

Rana R McKay
principal investigator · Yale University Cancer Center LAO

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion